Health IssuesProvide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies, EPIC Act; Most Favored Nation (MFN) policy, drug pricing policiesLobbied: HOUSE OF REPRESENTATIVES, SENATE
Medicare/MedicaidProvide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC ActLobbied: HOUSE OF REPRESENTATIVES, SENATE
The report’s record: the firm and its client, the income or expenses, each issue with the report’s own words and the agencies lobbied, and every amendment.
Source: lda.gov, the Secretary of the Senate’s and the Clerk of the House’s Lobbying Disclosure Act reports, read . Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.